Aytu Biopharma Share Price (NASDAQ: AYTU)

$2.36

▲

0.05

(2.16%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Aytu Biopharma Stock chart to analyse performance

Aytu Biopharma stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$2.26
Today's High:$2.40
$2.36
4.24%
Downside
Day's Volatility :5.83%
Upside
1.67%
52 Weeks Low:$0.95
52 Weeks High:$2.85
$2.36
59.75%
Downside
52 Weeks Volatility :66.67%
Upside
17.19%

Aytu Biopharma Stock Returns

Period	Aytu Biopharma Inc	Index (Russel 2000)
3 Months	34.83%	0.0%
6 Months	90.48%	0.0%
1 Year	-3.61%	0.0%
3 Years	-46.67%	-4.7%

Aytu Biopharma Inc Key Stats

Check Aytu Biopharma key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.31
Open	$2.3
Today's High	$2.4
Today's Low	$2.26
Market Capitalization	$20.7M
Today's Volume	$65.6K
52 Week High	$2.85
52 Week Low	$0.95
Revenue TTM	$81.7M
EBITDA	$6.0M
Earnings Per Share (EPS)	$-1.49
Profit Margin	2.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-3.06%

Stock Returns calculator for Aytu Biopharma Stock including INR - Dollar returns

The Aytu Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Aytu Biopharma investment value today

Current value as on today

₹99,684

Returns

₹316

(-0.32%)

Returns from Aytu Biopharma Stock

₹5,600 (-5.6%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Aytu Biopharma Stock

-65%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Aytu Biopharma Stock from India on INDmoney has decreased by -65% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Aytu Biopharma Inc

Name
Holdings %
Name
Holdings %
Nantahala Capital Management, LLC
12.11%
Stonepine Capital Management Llc
9.05%
Awm Investment Company Inc
6.91%
Kanen Wealth Management LLC
6.39%
Renaissance Technologies Corp
0.86%
Geode Capital Management, LLC
0.60%

Analyst Recommendation on Aytu Biopharma Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Aytu Biopharma(by analysts ranked 0 to 5 stars)

Aytu Biopharma Share Price Target

What analysts predicted

Upside of 344.92%

Target:

$10.50

Current:

$2.36

Aytu Biopharma share price target is $10.50, a slight Upside of 344.92% compared to current price of $2.36 as per analysts' prediction.

Aytu Biopharma Stock Insights

Price Movement
In the last 7 days, AYTU stock has moved up by 9.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 16.22M → 18.45M (in $), with an average increase of 12.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 788.0K → 3.99M (in $), with an average increase of 80.3% per quarter
AYTU vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 13.9%
AYTU vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 35.1% return, outperforming this stock by 82.2%
Price to Sales
ForAYTU every $1 of sales, investors are willing to pay $0.2, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Aytu Biopharma Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$7.3M	↑ 100.01%
Net Income	$-47.2M	↑ 362.97%
Net Profit Margin	-644.33%	↓ 365.97%

	FY20	Y/Y Change
Revenue	$27.6M	↑ 277.47%
Net Income	$-13.6M	↓ 71.12%
Net Profit Margin	-49.29%	↑ 595.04%

	FY21	Y/Y Change
Revenue	$65.6M	↑ 137.52%
Net Income	$-58.3M	↑ 327.97%
Net Profit Margin	-88.81%	↓ 39.52%

	FY22	Y/Y Change
Revenue	$96.7M	↑ 47.29%
Net Income	$-108.8M	↑ 86.62%
Net Profit Margin	-112.53%	↓ 23.72%

	FY23	Y/Y Change
Revenue	$107.4M	↑ 11.1%
Net Income	$-17.1M	↓ 84.33%
Net Profit Margin	-15.88%	↑ 96.65%

	FY24	Y/Y Change
Revenue	$81.0M	↓ 24.58%
Net Income	$-15.8M	↓ 7.08%
Net Profit Margin	-19.56%	↓ 3.68%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$22.9M	↑ 28.72%
Net Income	$-220.0K	↓ 97.29%
Net Profit Margin	-0.96%	↑ 44.61%

	Q1 FY24	Q/Q Change
Revenue	$14.0M	↓ 38.85%
Net Income	$-2.9M	↑ 1213.64%
Net Profit Margin	-20.61%	↓ 19.65%

	Q2 FY24	Q/Q Change
Revenue	$18.0M	↑ 28.17%
Net Income	$-4.6M	↑ 59.76%
Net Profit Margin	-25.68%	↓ 5.07%

	Q3 FY24	Q/Q Change
Revenue	$16.6M	↓ 7.8%
Net Income	$1.5M	↓ 131.93%
Net Profit Margin	8.89%	↑ 34.57%

	Q4 FY24	Q/Q Change
Revenue	$16.2M	↓ 2.13%
Net Income	$788.0K	↓ 46.54%
Net Profit Margin	4.86%	↓ 4.03%

	Q1 FY25	Q/Q Change
Revenue	$18.5M	↑ 13.75%
Net Income	$4.0M	↑ 406.85%
Net Profit Margin	21.65%	↑ 16.79%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$5.1M	↑ 218.02%

	FY20	Y/Y Change
Profit	$20.1M	↑ 292.3%

	FY21	Y/Y Change
Profit	$29.2M	↑ 45.43%

	FY22	Y/Y Change
Profit	$46.4M	↑ 59.04%

	FY23	Y/Y Change
Profit	$66.6M	↑ 43.48%

	FY24	Y/Y Change
Profit	$49.4M	↓ 25.9%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$14.6M	↑ 12.0%

	Q1 FY24	Q/Q Change
Profit	$11.7M	↓ 19.93%

	Q2 FY24	Q/Q Change
Profit	$11.9M	↑ 1.82%

	Q3 FY24	Q/Q Change
Profit	$12.0M	↑ 0.66%

	Q4 FY24	Q/Q Change
Profit	$10.8M	↓ 10.0%

	Q1 FY25	Q/Q Change
Profit	$12.8M	↑ 18.73%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-13.8M	↓ 13.23%
Investing Cash Flow	$-1.1M	↑ 119.29%
Financing Cash Flow	$19.1M	↓ 15.82%

	FY20	Y/Y Change
Operating Cash Flow	$-28.4M	↑ 105.14%
Investing Cash Flow	$-5.7M	↑ 432.57%
Financing Cash Flow	$71.1M	↑ 272.57%

	FY21	Y/Y Change
Operating Cash Flow	$-26.0M	↓ 8.49%
Investing Cash Flow	$-2.8M	↓ 50.81%
Financing Cash Flow	$30.3M	↓ 57.35%

	FY22	Y/Y Change
Operating Cash Flow	$-28.8M	↑ 11.01%
Investing Cash Flow	$-3.2M	↑ 16.75%
Financing Cash Flow	$1.5M	↓ 94.95%

	FY23	Y/Y Change
Operating Cash Flow	$-5.1M	↓ 82.21%
Investing Cash Flow	$-117.0K	↓ 96.4%
Financing Cash Flow	$8.9M	↑ 479.8%

	FY24	Y/Y Change
Operating Cash Flow	$-1.4M	↓ 72.94%
Investing Cash Flow	$-329.0K	↑ 181.2%
Financing Cash Flow	$-1.3M	↓ 114.23%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-135.0K	↓ 36.02%
Investing Cash Flow	$-174.0K	↑ 128.95%
Financing Cash Flow	$-126.0K	↓ 95.39%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-254.0K	↑ 88.15%
Investing Cash Flow	$-45.0K	↓ 74.14%
Financing Cash Flow	$530.0K	↓ 520.63%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-788.0K	↑ 210.24%
Investing Cash Flow	$-34.0K	↓ 24.44%
Financing Cash Flow	$1.1M	↑ 101.51%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-1.2M	↑ 51.02%
Investing Cash Flow	$381.0K	↓ 1220.59%
Financing Cash Flow	$911.0K	↓ 14.7%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.9M	↓ 344.12%
Investing Cash Flow	$145.0K	↓ 61.94%
Financing Cash Flow	$-2.8M	↓ 402.96%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-6.5M	↓ 322.2%
Investing Cash Flow	$-69.0K	↓ 147.59%
Financing Cash Flow	$4.3M	↓ 255.76%

Aytu Biopharma Technicals Summary

Sell

Neutral

Buy

Aytu Biopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Aytu Biopharma Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aytu Biopharma Inc	-1.64%	90.48%	-3.61%	-46.67%	-98.91%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aytu Biopharma Inc	NA	NA	0.0	-0.25	-0.03	-0.01	NA	5.66
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aytu Biopharma Inc	Buy	$20.7M	-98.91%	NA	2.01%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Aytu Biopharma Inc

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Organization	Aytu Biopharma
Employees	102
CEO	Mr. Joshua R. Disbrow
Industry	Consumer Services

Key Management of Aytu Biopharma Inc

Name	Title
Mr. Joshua R. Disbrow	CEO & Director
Mr. Jarrett T. Disbrow Ph.D.	Chief Business Officer
Mr. Greg Pyszczymuka	Chief Commercial Officer
Mr. Ryan J. Selhorn CPA	CFO, Corporate Secretary & Treasurer
Ms. Margaret Cabano	Vice President of Operations

Important FAQs about investing in AYTU Stock from India :

What is Aytu Biopharma share price today?

Aytu Biopharma share price today is $2.36 as on August 30, 2025 at 1:29 am IST at the close of the market. Aytu Biopharma share today touched a day high of $2.40 and a low of $2.26.

What is the 52 week high and 52 week low for Aytu Biopharma share?

Aytu Biopharma share touched a 52 week high of $2.85 and a 52 week low of $0.95. Aytu Biopharma stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $2.36, lower by 17.19% versus the 52 week high.

How to invest in Aytu Biopharma Stock (AYTU) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aytu Biopharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aytu Biopharma Shares that will get you 0.6356 shares as per Aytu Biopharma share price of $2.36 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Aytu Biopharma Stock (AYTU) from India?

Indian investors can start investing in Aytu Biopharma (AYTU) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Aytu Biopharma stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Aytu Biopharma share’s latest price of $2.36 as on August 30, 2025 at 1:29 am IST, you will get 4.2373 shares of Aytu Biopharma. Learn more about fractional shares .

What are the returns that Aytu Biopharma has given to Indian investors in the last 5 years?

Aytu Biopharma stock has given -98.91% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?